E-DRUG: Survey of incentives and enablers in HIV/AIDS Tx Progs
-------------------------------------------------------------
Dear Colleague(s),
As you know, more and more countries in the developing world are scaling up
access to antiretroviral drug therapy (ART) as part of their strategy for
addressing the HIV/AIDS epidemic. Although ART is not a cure, it provides
great hope for longer survival. However, provision of ART poses many
challenges to health care providers, health care systems, and the clients
they aim to reach.
Specific challenges include:
* Encouraging people to come forward for testing and counseling and, if
appropriate, treatment
* Encouraging HIV-positive pregnant women to accept and complete the full
course of preventive therapy, including treatment of the newborn, to prevent
HIV transmission
* Encouraging patients on ART to consistently adhere to the treatment
regimen
The USAID-supported Rational Pharmaceutical Management Plus (RPM Plus)
Program is conducting a survey to determine whether incentives and enablers
are being used in HIV/AIDS treatment programs and, if so, how and for what
purpose.
[For additional information on the background of this activity, please click
on the following link http://www.msh.org/projects/rpmplus/3.3.4.htm ]
The survey will be used to identify common challenges to ART access and
adherence as well as to understand what incentives and enablers are being
used as strategies to overcome these challenges. Based on the information
received, follow-up will take place to further catalog specific individual
experiences in more detail.
To participate in this survey, please either:
1. Click on the following link,
http://www.msh.org/projects/rpmplus/3.3.4survey.htm or
2. Send an e-mail to ajohnson@msh.org to request a hard copy of the survey
Please complete a separate copy of the survey for each incentive or enabler
being used.
We would appreciate receiving your responses by April 30th 2004.
We welcome any relevant documentation you are willing to share on the
design, implementation, and results of the incentive or enabler scheme(s)
used in your program.
Abiola Johnson and Alix Beith
RPM Plus/Management Sciences for Health
4301 N. Fairfax Drive, Suite 400
Arlington, VA 22203-1627
Tel: (1) 703 524 6575
Fax: (1) 703 524 7898
E-mail: surveyrpmplushiv@msh.org
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug